Lipoprotein(a) in clinical practice: A guide for the clinician

被引：9
|
作者：
Krittanawong, Chayakrit [1 ,2 ,11 ]
Maitra, Neil Sagar [3 ]
El-Sherbini, Adham H. [4 ]
Shah, Nishant [5 ]
Lavie, Carl J. [6 ]
Shapiro, Michael D. [7 ,8 ]
Virani, Salim S. [9 ,10 ]
机构：
[1] NYU Langone Hlth, Cardiol Div, NYU Langone Hlt, New York, NY USA
[2] NYU Sch Med, New York, NY USA
[3] Scripps Clin, Div Cardiol, La Jolla, CA 92037 USA
[4] Queens Univ, Fac Hlth Sci, Kingston, ON K7L 3N6, Canada
[5] Duke Univ, Duke Heart Ctr, Div Cardiol, 2301 Erwin RD, Durham, NC 27705 USA
[6] Univ Queensland, Sch Med, John Ochsner Heart & Vasc Inst, Ochsner Clin Sch, New Orleans, LA USA
[7] Wake Forest Univ, Bowman Gray Sch Med, Dept Med, Sect Cardiovasc Med, Winston Salem, NC USA
[8] Ctr Prevent Cardiovasc Dis, Med Ctr Blvd, Winston Salem, NC USA
[9] Baylor Coll Med, Dept Med, Sect Cardiol & Cardiovasc Res, Houston, TX 77030 USA
[10] Aga Khan Univ, Off Vice Provost Res, Karachi 74800, Pakistan
[11] NYU Sch Med, Cardiol Div, Sect Cardiol, 550 First Ave, New York, NY 10016 USA
来源：
PROGRESS IN CARDIOVASCULAR DISEASES | 2023年 / 79卷
关键词：
Atherosclerosis; Calcific aortic stenosis; Coronary artery disease; Dyslipidemia; Genetics; Lipoprotein(a); Pathophysiology; Risk factors; CORONARY-HEART-DISEASE; GENOME-WIDE ASSOCIATION; EXTENDED-RELEASE NIACIN; AORTIC-VALVE STENOSIS; OXIDIZED PHOSPHOLIPIDS; CARDIOVASCULAR EVENTS; FAMILIAL HYPERCHOLESTEROLEMIA; RAISED LIPOPROTEIN(A); RANDOMIZED-TRIAL; RESIDUAL RISK;
D O I：
10.1016/j.pcad.2023.07.006
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Cardiovascular disease (CVD) remains the leading cause of death worldwide. Serum lipoprotein(a) (Lp(a)) has been shown to be an independent and causative risk factor for atherosclerotic CVD and calcific aortic valvular disease. Lp(a) continues to be studied, with emerging insights into the epidemiology of CVD with respect to Lp (a), pathogenic mechanisms of Lp(a) and strategies to mitigate disease. There have been novel insights into genetic polymorphisms of the LPA gene, interactions between concomitant risk factors and Lp(a) based on realworld data, and metabolic pathway targets for Lp(a) reduction. This review highlights these recent advances in our understanding of Lp(a) and discusses management strategies as recommended by cardiovascular professional societies, emerging therapies for lowering Lp(a), and future directions in targeting Lp(a) to reduce CVD.
引用
收藏
页码：28 / 36
页数：9
相关论文
共 50 条
12345